Insider Trading History of Madden David

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) by Madden David since 2005. The trader's CIK number is 1230836. At the time of the last reporting, Madden David was the Chairman, President of Dicerna Pharmaceuticals Inc. (stock ticker symbol DRNA). Also see all insider trading activities at Dicerna Pharmaceuticals Inc.

Note that in the past MADDEN DAVID also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Dicerna Pharmaceuticals Inc (DRNA) by Madden David

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2014 DRNA 7,500 $112,500 0 $0 112,511 $384,787

Yearly summary of insider trading at Adolor Corp (ADLR) by Madden David

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2011 ADLR 80,075 $372,749 0 $0 265,000 $602,345
2006 ADLR 0 $0 0 $0 554,000 $6,919,460
2005 ADLR 50,000 $501,999 0 $0 0 $0


Insider trading activities at 2 companies by Madden David:

1. Dicerna Pharmaceuticals Inc (DRNA)

2. Adolor Corp (ADLR)

Table 1. Insider trading of Dicerna Pharmaceuticals Inc (DRNA) by Madden David

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2014-01-24 DRNA Option Ex 112,511 3.42 384,787
2014-01-29 DRNA Buy 7,500 15.00 112,500

Table 2. Insider trading of Adolor Corp (ADLR) by Madden David

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2011-12-08 ADLR Option Ex 265,000 2.27 602,345
2011-12-06 ADLR Buy 80,075 4.66 372,749
2006-05-05 ADLR Option Ex 554,000 12.49 6,919,460
2005-03-10 ADLR Buy 50,000 10.04 501,999

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Madden David (Chairman, President of Dicerna Pharmaceuticals Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.